Lupin Limited has informed the Exchange regarding a press release dated May 18, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution".
Lupin Limited has informed the Exchange regarding a press release dated May 18, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution".